Search hospitals
>
Illinois
>
Chicago
John H. Stroger Jr. Hospital of Cook County
Claim this profile
Chicago, Illinois 60612
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Breast Cancer
Conducts research for AIDS
Conducts research for Lung Cancer
369 reported clinical trials
6 medical researchers
Summary
John H. Stroger Jr. Hospital of Cook County is a medical facility located in Chicago, Illinois. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Breast Cancer, AIDS, Lung Cancer and other specialties. John H. Stroger Jr. Hospital of Cook County is involved with conducting 369 clinical trials across 513 conditions. There are 6 research doctors associated with this hospital, such as Thomas E. Lad, Paul Rubinstein, MD, Lakshmi Rajdev, and Janardhan Mydam, MD.
Area of expertise
HIV Infection
John H. Stroger Jr. Hospital of Cook County has run 101 trials for HIV Infection. Some of their research focus areas include:
Human Immunodeficiency Virus Infection
John H. Stroger Jr. Hospital of Cook County has run 86 trials for Human Immunodeficiency Virus Infection.
Top PIs
Thomas E. Lad
John H Stroger Jr Hospital of Cook County
3 years of reported clinical research
Paul Rubinstein, MD
University of Illinois
3 years of reported clinical research
Lakshmi Rajdev
Siteman Cancer Center at Washington University
10 years of reported clinical research
Janardhan Mydam, MD
John H. Stroger, Jr. Hospital of Cook County
8 years of reported clinical research
Clinical Trials running at John H. Stroger Jr. Hospital of Cook County
Lung Cancer
Ovarian Cancer
Breast Cancer
Cancer
Breast cancer
Esophageal cancer
Colorectal Cancer
Pancreatic Cancer
Prostate Cancer
Multiple Myeloma
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Blood Sample Collection
for Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Recruiting
1 award
N/A
9 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at John H. Stroger Jr. Hospital of Cook County?
John H. Stroger Jr. Hospital of Cook County is a medical facility located in Chicago, Illinois. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Breast Cancer, AIDS, Lung Cancer and other specialties. John H. Stroger Jr. Hospital of Cook County is involved with conducting 369 clinical trials across 513 conditions. There are 6 research doctors associated with this hospital, such as Thomas E. Lad, Paul Rubinstein, MD, Lakshmi Rajdev, and Janardhan Mydam, MD.
Where is John H. Stroger Jr. Hospital of Cook County located?
John H. Stroger Jr. Hospital of Cook County is located at 1969 W Ogden Ave, Chicago, IL. For public transportation, take the Chicago 'L' to the Illinois Medical District station, a short 5-minute walk to the hospital. If driving, directions can be easily found on Waze.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at John H. Stroger Jr. Hospital of Cook County, please contact: - Financial Assistance Office/Appointment with Financial Counselor: (866) 223-2817 - General Billing & Insurance: (866) 223-2817 or (312) 864-2224 - Paying for Healthcare Services: (312) 864-0200 These contacts are available for assistance with financial assistance applications, billing questions, insurance concerns, and inquiries related to healthcare costs.
What insurance does John H. Stroger Jr. Hospital of Cook County accept?
The John H. Stroger Jr. Hospital of Cook County accepts Medicaid, Medicare, Private Insurance, and Private Pay. They also offer the CareLink financial assistance program for Cook County residents who are uninsured or underinsured, covering a wide range of services including clinic visits, laboratory visits, hospital stays, prescriptions, and urgent and emergency care. To be eligible for CareLink, applicants must reside in Cook County, be uninsured or underinsured, and have an income below 600% of the Federal Poverty Line.
What awards or recognition has John H. Stroger Jr. Hospital of Cook County received?
John H. Stroger Jr. Hospital of Cook County, located in Chicago, Illinois, is recognized by U.S. News & World Report for high performance. It is affiliated with the National Cancer Institute's Minority-Based Community Clinical Oncology Program, offering access to national cooperative clinical trials in cancer treatment, prevention, and control. The hospital also engages in research in HIV, diabetes, and airway control, supported by funding from the National Cancer Institute and the Department of Defense.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.